Quality & complianceOfficial

DKMA flags Zyprexa 10 mg injection supply problem from Orifarm, end date unknown

🇩🇰 DKMA · Mon 26 Oct 2026

The Danish Medicines Agency lists Orifarm's olanzapine powder for solution for injection as affected by delivery difficulties, with no end date given.

The Danish Medicines Agency (DKMA) has published a supply notice for Zyprexa 10 mg powder for solution for injection, supplied in Denmark by Orifarm A/S. The notice, dated 26 October 2026, says there are current problems with supply of the product.

The active substance is olanzapine, ATC code N05AH03. DKMA gives the cause as delivery difficulties and does not elaborate on what lies behind them.

The expected period of disruption is listed as starting at the end of April 2026, with the end date shown as unknown. The notice does not say when normal supply might resume.

DKMA directs anyone with questions about the current status to the company. The notice does not name alternative products or set out any mitigation measures.

What it means for your team

  • Supply-chain and pharmacy teams in Denmark should treat availability of Zyprexa 10 mg injection from Orifarm as uncertain, because DKMA gives no end date.
  • The notice names no alternatives, so teams will need to approach Orifarm directly for current status, as DKMA advises.
  • Regulatory and market-access staff tracking Danish shortages can log the entry, with its cause given as delivery difficulties and its expected start in late April 2026.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →